Killer Ig-like receptor (KIR) is a major cluster of the natural killer cell receptors and may play a role in the outcome of hematopoietic cell transplants. A total of 65 AML cases transplanted with T-replete hematopoietic cells from unrelated donors were retrospectively KIRgenotyped by a multiplex PCR method of our own design. The KIR gene frequency and genotype patterns in these 130 samples were consistent with the data in the literature. Based upon overall inhibitory and activating KIR genes in both donors and patients, we developed an algorithm to calculate a compatibility score for each transplant case as plus, zero or minus. Significantly higher incidence (18/20, 90%) of acute (a) GVHD (grade II-IV) was found in the transplant cases with plus scores than that (25/45, 56%) in the cases with zero or minus scores (Po0.01). When the scores are sorted in the opposite way, fewer cases (13/26, 50%) of aGVHD were found in the transplants with minus scores than that (30/39, 77%) in the transplants with zero or plus scores (Po0.05). The difference of aGVHD prevalence between the plus score and minus score groups is highly significant (Po0.01). KIR genotype compatibility calculated by this algorithm may predict aGVHD incidence and be helpful in choosing donors. Bone Marrow Transplantation (2005) 36, 525-530.
hematopoietic cell transplantation; acute GVHD Natural killer (NK) cells, the third major lymphocyte population, participate in early innate immune responses, and may play an important role in immune surveillance. They may also link the innate immune system to the adaptive immune system. [1] [2] [3] NK cells may affect the outcome of hematopoietic cell transplants (HCT) due to not only their role in the immune system but also their control of hematopoiesis. NK cells are also the first lymphocyte subset to reconstitute the peripheral blood of HCT patients. [4] [5] [6] Killer Ig-like receptors (KIRs), consisting of inhibitory and activating groups, are expressed on NK cells as well as on a subset of T cells. At least 14 functional KIR genes and two KIR pseudogenes have been defined. The KIR gene cluster is located on chromosome 19q13.4. 7, 8 Some of the inhibitory KIRs recognize specific HLA class I epitopes. These include the well-defined specificity of KIR 2DL2/3 for the HLA-Cw group-1 epitope (Asparagine at codon 80, Cw1, 3, etc), the specificity of 2DL1 for the Cw group-2 epitope (Lysine at codon 80, Cw2, 4, etc), and the specificity of 3DL1 for HLA Bw4. The ligands for activating KIRs have not yet been identified conclusively. Interaction of inhibitory KIRs with specific HLA class I epitopes regulates the activities of NK cells. 1, [9] [10] [11] [12] There are currently different models designed to determine the efficacy of KIR mismatching, or matching on the outcome of HCT may be classified into three categories. The first one is that the mismatch of KIR ligand benefits HCT patients with increased overall survival and decreased leukemia relapse rates, [13] [14] [15] but not consistently observed by several groups. [16] [17] [18] [19] The second category addresses KIR effects in HLA identical transplants. 'Missing KIR ligand' instead of the 'missing self' model was proposed. In an HLA-identical HCT pair, if they are homozygous for HLA-Cw group 1, 2, and/or Bw6 and positive for 2DL2/3, 2DL1, and/or 3DL1, these inhibitory KIRs lack ligands and the NK cells could pose alloreactivity to other tissues. 5, 11, 20 The third category analyzes only the KIR genotype to address its role in the clinical course of HCT patients, which includes Gagne's model of 'the patients' KIR genotypes included in their donors' KIR genotype', 21 Bishara's model of 'donors having four or more activating KIRs', 22 the model of donors with KIR haplotype B, 23, 24 and the one of donors positive for 2DS1 and 2DS2. 25 To test these models, we performed a retrospective study on 65 AML patients transplanted with T-replete hematopoietic cells from unrelated donors (UDs). Analysis of our data, as described in the models discussed above, did not confirm their predicted conclusions. We then developed an algorithm to calculate a compatibility score of KIR genotypes between each transplant pair, which is a significant predictor of acute (a) GVHD (Po0.01).
Patients and methods

Patients and transplant method
A total of 65 consecutive AML patients who received UD transplants from 1999 to June 2003 were enrolled in this study. Consents were obtained in compliance with an IRBapproved protocol. Transplant preparation included UD selection prospectively based upon HLA compatibility and other factors, such as CMV status, gender, donor age, blood group, etc; diversified protocols for conditioning included TBI and other nonradiation reagents; and institutional standard aGVHD prophylaxis using a short course of CsA and methotrexate. Neither T-cell depletion nor ATG were used in the transplant protocol. The ethnicity background of the 130 individuals consisted of Caucasoid (75%), Hispanic (20%), and others (5%).
HLA and KIR genotyping
HLA typing of patients and donors was performed before HCT with high-resolution DNA-based methods for A, B, Cw, DRB1, and DQB1. Two-allele mismatches were counted as mismatched transplants. A multiplex PCR-SSP method, described previously, was used to type the KIR genes for the 130 genomic DNA samples. The method was validated with the NK/KIR panel II from the IHWG. 26 We recently joined the UCLA DNA exchange for KIR genotyping with this method and were 100% concordant. Clear-cut results were obtained on all 130 samples.
Clinical study end points
Diagnoses of remission and leukemic relapse were based on cytomorphology and flow cytometry. The diagnosis and grading of aGVHD followed the commonly accepted definitions, 27 aGVHD graded as I-IV and no aGVHD graded as 0. Overall survival (OS) was calculated for the interval between the dates of transplantation and the last follow-up visit or death. Disease-free survival (DFS) was defined for the interval between the dates of transplantation in hematologic remission and either first relapse or death from any cause.
Statistical analysis
Data regarding patient characteristics, transplant protocols, post transplantation complications, and other outcomes were retrieved from our hospital information database and verified by the Division of Information Sciences. Fisher's exact test was used to compare proportions of patients with aGVHD between various groupings of the data. The Cochran-Armitage test for trend was used in cases of ordinal predictor variables. The Wilcoxon ranksum test was used to test the difference of age at transplant. Survival outcomes were calculated as time in years from transplant date until event or last contact. Kaplan-Meier survival estimates were tested using the Mantel-Haenszel (log-rank) test. 95% confidence Intervals on the KaplanMeier estimates were calculated using a logit transformation of Greenwood's estimate of the variance. The median follow-up time of survivors was 34 months (range, 8-77 months). Logistic regression was employed in developing multivariate models with the outcome of aGVHD.
Results
KIR gene patterns in this cohort
We observed 42 genotypes defined with the 2DS4 deletion variant. There were only five (4%) individuals typed as 2DL1 gene negative and six (5%) typed as 3DL1 negative. 2DS5 was the least frequent gene, and was found in only 35 (27%) people in this cohort. The KIR genotype information from this study is consistent with most of the data in the literature. 21, 28, 29 2DL4 is a framework gene in the KIR gene cluster, and is conserved in most individuals. Observed haplotypes lacking 2DL4 are very rare, 7,30 but we did find a person in this small cohort KIR-genotyped as 2DL4 negative, which suggested that both haplotypes in this person either lack the gene or contain new alleles with variance in the targeted sequence of our primer set (data not shown).
Our KIR genotyping method cannot define haplotype except in homozygous individuals. KIR haplotype A consists of only one activating KIR (2DS4), and is the most common haplotype. Haplotype A splits into A1 and A2 based on the presence of normal 2DS4, or its deletion variant. A2 is about three times more frequent than A1. 1, 7, 11 In our cohort, there were 22 (17%) A2 homozygotes, 17 (13%) A1A2 heterozygotes, and only three (2.3%) A1 homozygotes. KIR genotyping demonstrated that 14 (22%, regardless of the 2DS4 deletion variants), or nine (14%, considering the 2DS4 deletion) transplant patients had a KIR gene-matched donor due to the high frequency of the KIR A2-haplotype.
Development of an algorithm calculating KIR genotype compatibility to predict aGVHD
We developed an algorithm that considers all inhibitory and activating KIRs in both patients and donors, and assigns a 'compatibility score' for each transplant pair. Table 1 lists the criteria to calculate the 'compatibility score' of each KIR gene locus. 2DL2 and 2DL3 are Table 1 Criteria to assign the compatibility score of each KIR gene between a transplant pair
KIR gene Score
Patient Donor
counted as one gene, because they recognize the same ligand. The 2DS4 deletion variant that does not encode a membrane-bound KIR is not included because the function of truncated soluble 2DS4 is not known yet. All scores from every locus were combined on an Excel worksheet to generate a final score for each transplant pair. Table 2 demonstrates the value of the compatibility score in predicting aGVHD. Analysis was first performed in binary variables as cases without aGVHD (grade 0) versus (vs) the cases with aGVHD (I-IV), 0-I vs II-IV, or 0-I vs III-IV against the positive score transplants vs others, negative scores vs others, or positive scores vs negative scores. The prevalence of aGVHD is significantly different (Po0.01 or o0.05, bolded) among groups for all comparisons, except two. It is noteworthy that when the comparison was performed without the zero score and/or aGVHD grade II cases (less number of cases, decreased statistical power), the difference remained at the same significant level (Po0.01 or o0.05), indicating that both ends of the binary variables associated well (Table 2a) . Then the grade of aGVHD was further analyzed between positive, zero and negative scores for trend, and the difference is still very significant (Po0.01, Table 2b ). The algorithm is a good predictor of aGVHD. However, no significant relationship was identified between the estimated OS ( Figure 1a) or DFS (Figure 1b ) and the calculated KIR gene compatible score.
There was also no significant relationship found in other clinical end points, such as relapse and graft failure, may be due to the small cohort study.
Incidence of aGVHD and other HCT outcomes depend on multiple factors, including HLA identity between the donor and recipient, patient age, disease status, conditioning regimen, aGVHD prophylaxis regimen, etc. All the clinically common factors listed in Table 3 did not significantly affect the prevalence of aGVHD, except fractioned (f) TBI. Multivariate analysis demonstrated that the score was an independent factor affecting aGVHD (Table 4) .
Analyses of this cohort with current models
Our data were analyzed with the aforementioned models before the compatibility algorithm was developed. In terms of the criteria of the 'missing-self' model previously described 15 plus corresponding inhibitory KIR present in donors, there were only 12 KIR ligand mismatches at both vectors out of 22 HLA-B or Cw mismatched transplants. Overall Survival by Score N=65 The number was too small to reach any statistically significant conclusions (Table 5) .
For the overall 'missing KIR ligands' followed for the definition previously described, 5 there was a trend of more (74 vs 52%) moderate to severe aGVHD (II-IV) in patients lacking HLA ligand for donors inhibitory KIR, but it was not statistically significant (Table 5 ). Cook's criterion, 20 a patient homozygous for HLA-Cw group 2 plus a 2DS2-positive donor, is not applicable to our cohort because only two cases met the condition (data not show). In KIR genotype patterns between patients and donors, based on Gagne's model, 21 our study demonstrated a similar trend of more aGVHD when the patients' KIR genotypes were included in the donors' than the opposite (80 vs 47%), although it is still not statistically significant. Bishara's finding, higher probability of aGVHD in a transplant with a donor having four or more activating KIR genes, 22 was not observed in our study. Donors positive for KIR haplotype B did not make any difference in the rate of aGVHD (Table 5) .
Other major clinical end points, like survival, relapse, etc, were also analyzed with the above criteria and no significant difference was detected (data not shown). We perceived a connection between Gagne's model and Bishara's. 31 When the recipient KIR genotype was included in the donor most of them had less activating KIRs than their donors. A donor who has four or more activating KIRs often has a recipient with fewer activating KIRs, because the maximum activating KIR genes presenting in an individual is six. Then we developed the algorithm that is the best predictor of aGVHD in this cohort.
Discussion
The present pilot study developed an algorithm that correlates very well the KIR genotype compatibility with Table 3 Relation of patients characteristics and transplant (Tx) procedures to aGVHD aGVHD P-value the incidence of aGVHD. In contrast, no significant differences in this cohort were revealed by most models that were used to address the effects of KIR ligands and/or genotypes on the outcomes of HCT in other studies. 5, 11, [13] [14] [15] [20] [21] [22] [23] [24] [25] The algorithm belongs to category 3, considering KIR only, but has the characteristics described below. It qualitatively compares the KIR genotypes between patients and donors, considers the 2DL2 and 2DL3 as a single gene, and does not count the 2DS4 deletion variant as 2DS4 positive. All these criteria increased the predictive capability of aGVHD. Although the algorithm has no predictive ability on patient survival, graft failure, and leukemia relapse in this small cohort, perhaps due to T-replete transplants, small cohort study, and/or other opposite effects, prediction of aGVHD may be useful in guiding the usage of prophylactic regimens for aGVHD and in choosing an appropriate donor (one less likely to manifest aGVHD), when there are multiple donors available. The finding underscores the importance of a large-scale and multicenter study using this approach, and viewing KIR effects from different angles, especially when the knowledge about activating KIRs and the role of NK cells in HCT has not been well developed.
In the models considering KIR only, comparison of KIR genotypes between HCT pairs started in 2002. 21 We have tried to quantify the KIR gene compatibility, considering both inhibitory and activating KIRs. 31 Others have found a significant higher graft rejection rate in the KIR genotype identical HCTs 32 or a decreased survival rate associated with the number of R þ (recipient)DÀ(donor) activating KIR. 33 However, it is hard to explain this phenomenon with current NK cell biology. KIR is a receptor that interacts with its ligand to function. KIR receptors segregate independently of KIR profiles in HCT pairs. One of the possible explanations for the triggering of NK cells may be determined by the overall balance of signaling between inhibitory and activating receptors. Many activating KIR ligands are unknown, 34 although some activating KIRs may bind inhibitory KIR ligands with low affinity. 1, 6, 9 Activating KIR ligands could be expressed in tissues of the skin, liver, and gut. Comparison of the transplants with donors having more activating KIR and the transplants with the others, the unknown activating KIR ligands, would be diversified. The presence of sufficient donor activating KIRs may overcome the remaining inhibition and trigger killing function. Disease disposition associated with KIR genes or genotypes themselves 35, 36 also supports the usefulness of studying KIR genotypes with HCT outcomes. One may assume that KIR genotype mismatch could create some unknown mHA leading to aGVHD. However, whether in Gagne's model (recipient's KIR genotype included in a donor's), in Bishara's model (donor having four or more activating KIR), or in our positive score group, donors have more KIR proteins expressed so that mHA should lead to graft failure instead of GVHD.
The phenomena of KIR ligands and/or genotypes affecting clinical outcomes of HCT in diverse settings have been reported by multiple transplantation centers. Some reached a limited consensus, 5, [13] [14] [15] while others remain controversial. [16] [17] [18] [19] [20] The disparities may be explained by differences in patient age, disease stage, transplant material, and/or protocol. 19, 37 A KIR ligand mismatch model is supported by the 'missing self-theory' that explains NK cell alloreactivity. Transplants under this model are often obtainable between single haploidentical relatives. Among mismatched UD transplants, only a few are also KIR ligand mismatched. Most of the studies using this model predicted KIR ligand mismatch solely based on HLA type (Ligand-Ligand Model). Owing to the independent segregation of KIR genes and their ligand HLA genes, some recipient and donor pairs are thought to have a KIR ligand mismatch, but in reality there is no mismatch because the donors do not have the corresponding KIR gene. For example, 5% of Caucasians lack KIR 3DL1 and 8% lack 2DL1. 31, 28, 29 Analyses of donor and recipient KIR ligands in combination with KIR genotype 21, 22 or KIR expression 38 may result in better interpretation of clinical outcomes in regards to KIR ligand mismatching. These studies represent a shift from the 'Ligand-Ligand Model' to the 'Receptor-Ligand Model' in the category 1.
To increase the efficacy of NK cells in HCT, T-cell depletion appears to be important and reasonable because T-cells can overwhelm any NK effects. How stringent should the ex vivo T-cell depletion be? Bishara's group demonstrated that the difference between an average of 3 Â 10 4 vs 10.8 Â 10 4 residual T-cells/kg could result in different clinical outcomes. 22 Antithymocyte Ig or OKT3 administration to patients could reach some level of donor T-cell depletion in vivo, but no data have shown how complete this could be, and what dosage can optimize the T-cell depletion without increasing other clinically related risk factors. However, some reports did not emphasize the T-cell depletion factor, 20, 21 while others reported the effect of KIRs on long-term antileukemic efficacy 15 or CMV reactivation 23 in unmodified allogeneic HCT. These studies implied that, in the T cell-replete HCT, NK cells could still play a role. Higher prevalence of aGVHD without a significant difference of overall survival in the positivescore group of our study may imply that the NK effect is short lived. A larger cohort will be needed to determine if this is reproducible.
